249 related articles for article (PubMed ID: 33311988)
1. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.
Zhang EL; Zhang ZY; Li J; Huang ZY
Onco Targets Ther; 2020; 13():12477-12487. PubMed ID: 33311988
[TBL] [Abstract][Full Text] [Related]
2. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
3. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma.
Joerger M; Güller U; Bastian S; Driessen C; von Moos R
J Gastrointest Oncol; 2019 Apr; 10(2):373-378. PubMed ID: 31032109
[TBL] [Abstract][Full Text] [Related]
4. [Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Takeda Y; Ohmura Y; Katsura Y; Sakamoto T; Nose Y; Mori R; Inatome J; Kawai K; Naito A; Murakami K; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Murata K
Gan To Kagaku Ryoho; 2019 Mar; 46(3):532-536. PubMed ID: 30914605
[TBL] [Abstract][Full Text] [Related]
5. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Advanced Hepatocellular Carcinoma Successfully Treated with Liver Resection after Administration of Sorafenib].
Kodai S; Kanazawa A; Kinoshita M; Hamano G; Nishio K; Murata A; Shimizu S; Kikuchi T; Yonemitsu K; Shirai D; Nobori C; Tashima T; Goto W; Miura K; Maeda K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):502-504. PubMed ID: 32381929
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Takeda Y; Kido H; Iida N; Kitahara M; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2021 Feb; 51(2):190-200. PubMed ID: 33197087
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.
Uchikawa S; Kawaoka T; Aikata H; Kodama K; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Hepatol Res; 2018 Sep; 48(10):814-820. PubMed ID: 29682855
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
12. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma.
Katafuchi E; Takami Y; Wada Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
Case Rep Gastroenterol; 2015; 9(2):285-90. PubMed ID: 26351418
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
16. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
17. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
[TBL] [Abstract][Full Text] [Related]
18. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
19. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
[TBL] [Abstract][Full Text] [Related]
20. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
Trojan J; Waidmann O
J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
